PRISM2: Unlocking Multi-Modal General Pathology AI with Clinical Dialogue
Eugene Vorontsov, George Shaikovski, Adam Casson, Julian Viret, Eric Zimmermann, Neil Tenenholtz, Yi Kan Wang, Jan H. Bernhard, Ran A. Godrich, Juan A. Retamero, Jinru Shia, Mithat Gonen, Martin R. Weiser, David S. Klimstra, Razik Yousfi, Nicolo Fusi, Thomas J. Fuchs, Kristen Severson, Siqi Liu
TL;DR
PRISM2 addresses the need for slide-level, generalizable pathology representations by aligning histomorphology with diagnostic language through clinical-dialogue supervision. It introduces a slide-level multimodal foundation model that yields two embedding types (base and diagnostic) via a two-stage training pipeline integrating a perceiver-based slide encoder, BioGPT text encoder, and Phi-3 Mini LLM, trained on a large corpus of specimen-report pairs and QA data. The approach achieves clinical-grade cancer detection with direct QA without task-specific fine-tuning, and demonstrates strong transfer to biomarker and survival tasks, plus the ability to complete CAP-style pathology reports. Overall, the work shows language-guided pretraining as a scalable, clinically grounded signal that bridges human diagnostic reasoning and foundation-model performance, with potential to enhance diagnostic workflows and prognostic assessments in pathology.
Abstract
Recent rapid progress in the field of computational pathology has been enabled by foundation models. These models are beginning to move beyond encoding image patches towards whole-slide understanding but their clinical utility remains limited. In this work, we present PRISM2, a multimodal slide-level foundation model trained on data from 700,000 diagnostic specimen-report pairs, the largest vision (2.3 million whole slide images) and language (14M question-answer pairs) histopathology dataset to date. By learning through clinical-dialogue supervision, PRISM2 aligns histomorphologic features with the language of diagnostic reasoning, producing slide-level representations that support both direct diagnostic question-answering and transferable embeddings for downstream tasks. Without additional training, PRISM2 matches or exceeds the cancer-detection performance of clinical-grade products. This is observed without loss of generality on other tasks, where PRISM2 achieves top performance. Finally, using survival prediction as the example, we show that task-specific finetuning with a large dataset can outperform task-specific models, further improving performance. These results demonstrate how language-supervised pretraining provides a scalable, clinically grounded signal for learning generalizable pathology representations, bridging human diagnostic reasoning and foundation-model performance.
